BCMA-targeted CAR-T

**BCMA-targeted CAR-T** refers to chimeric antigen receptor T-cell therapies engineered to target B-cell maturation antigen (BCMA, encoded by TNFRSF17), a protein highly expressed on malignant plasma cells in multiple myeloma (MM). These autologous T cells are genetically modified to express a CAR with an anti-BCMA single-chain variable fragment (scFv), typically linked to CD28 or 4-1BB costimulatory domains and CD3ζ for T-cell activation, enabling specific cytotoxicity against BCMA-expressing MM cells. Approved products like idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have demonstrated high overall response rates (70-98%) in relapsed/refractory MM, though relapses often occur due to BCMA-low/negative escape, trogocytosis, or immune exhaustion. Developers include Bristol Myers Squibb (ide-cel), Janssen/Legend Biotech (cilta-cel), and others like bluebird bio, Celgene, and Novartis for investigational constructs; primary indication is triple-class exposed RRMM.

Other names

BCMA CAR-Tanti-BCMA CAR-T